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South KoreaObjective. Superior mesenteric vein thrombosis (SMVT) is generally difficult to diagnose and can be fatal. Mesenteric and
portal vein thrombosis is rare and can be presented as more serious conditions than that of SMVT. We report patients with
combined SMVT and portal vein thrombosis (PVT) who were treated successfully with early initiation of anticoagulation.
Methods. The medical records of six patients (five male, one female) who presented with combined SMVTand PVT in our
institute between January 1994 and September 2003 were reviewed retrospectively. All of the patients were treated with early
initiation of anticoagulation using unfractionated heparin or low molecular weight heparin.
Results. The mean hospital stay was 31 days and the mean follow-up period was 32 months. Three patients had an
antithrombin III deficiency. The most common symptom was diffuse abdominal pain and signs included abdominal
distension and tenderness. During the follow-up period, there were two patients who developed stricture of the small bowel
necessitating resection and anastomosis of the small bowel. There was no case of peritonitis due to bowel necrosis or
mortality.
Conclusion. The early initiation of anticoagulation in patients of SMVT combined with PVT could minimise the serious
complication such as peritonitis due to bowel necrosis required immediate exploratory laparotomy.Keywords: Superior mesenteric vein thrombosis; Portal vein thrombosis; Anticoagulation.Introduction
Superior mesenteric vein thrombosis (SMVT) is an
uncommon cause of mesenteric ischaemia. It was first
recognised more than 100 years ago by Eliot,1 who
described intestinal gangrene resulting from mesen-
teric venous occlusion. In 1913, Trotter reported that
41% of patients withmesenteric ischaemia had SMVT.2
The subject remained virtually unexplored until 1935
when Warren and Eberhardt reported two personal
cases and collected 73 others from published reports.3
At the time of their publication, SMVT became
recognised as a distinct clinical entity. They reported
a mortality rate of 34%. Additionally, they found that
only 5% of patients who did not undergo surgical
treatment survived. Unfortunately, this mortality rate
still holds despite improvements in therapy.
SMVTcombined with portal vein thrombosis (PVT)
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potentially fatal. Because the symptoms are not
specific, the diagnosis and initial treatment are often
being delayed, but once SMVTand PVTare suspected,
computed tomography (CT) scan should be performed
promptly. In cases with signs of peritonitis, transmural
bowel infarction, or haemodynamic instability require
immediate exploratory laparotomy.4 However, there is
a few recent reports in which SMVT combined with
PVT was successfully treated by anticoagulation
therapy alone and close follow-up.5,6
We report six cases of combined thrombosis of the
superior mesenteric (SMV) and portal veins (PV)
which we treated by early initiation of anticoagulation
without surgical or radiological intervention.Patients
Between January 1994 and September 2003, we treated
15 patients (10 men, and five women) with superior
mesenteric thrombosis (SMVT) and/or portal vein
thrombosis (PVT). There were one PVT, eight SMVTEur J Vasc Endovasc Surg 29, 204–208 (2005)
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were diagnosed by abdominal CTscanning. A positive
CT scan consisted of the enlargement of the throm-
bosed vein, a central area of low attenuation repre-
senting intraluminal thrombus, and the vein wall
sharply delineated by a hyperlucent rim of tissue.
One case of PVT occurred in a patient with
advanced gastric cancer with multiple liver metastasis.
This patient presented with oesophageal variceal
bleeding necessitating endoscopic variceal ligation
without anticoagulation treatment. Eight cases of
SMVT were treated by anticoagulation with heparin
followed by warfarin.
In this series, we reviewed six cases of SMVT
combined with PVT. There were five men and one
woman with an average age of 45 (range: 31–70 years).
The patient characteristics, conditions predisposing to
thrombosis, symptoms and signs at admission, CT
scan findings of abdomen, extent of thrombus, use of
heparin, and complications were analysed. Blood
sampling for thrombophilic disorders was done prior
to anticoagulation therapy.ResultsConditions associated with thrombosis
Three patients had an antithrombin III deficiency. One
out of three patients had combined protein C and
protein S deficiency. This patient also had liver
cirrhosis of Child B classification. There was one
patient with inflammation and swelling of the vermi-
form appendix. There was one patient with diverticu-
litis of the colon.Symptoms and signs at admission
All of the patients were admitted through the
emergency department with diffuse abdominal pain,
severe abdominal distension, and tenderness. Three
patients showed rebound tenderness. One patient had
ascites detected clinically with a fluid wave on
physical examination and three patients had ascites
detected by CT scanning.Diagnostic evaluation
SMVT and PVT was diagnosed by abdominal CT
scanning. All patients showed typical positive find-
ings of CT scan (Fig. 1). The patient was followed up
with CT scan for evaluating the disease progression(Figs. 2 and 3). The stricture of the small bowel was
diagnosed primarily on the basis of clinical findings
and definitely on the basis of the small bowel series
(Fig. 4).Extent of thrombus
Among the six patients with combined SMVT and
PVT, one patient showed combined splenic vein
thrombosis, one iliac vein thrombosis, one splenic
and iliac vein thrombosis.Patient management
All patients were treated with anticoagulation, anti-
biotics, and total parenteral nutrition (TPN) as soon as
they were diagnosed with SMVT combined with PVT.
Nadroparine calcium 2850 IU was given 12 hourly in
two patients, enoxaparin sodium 40 mg was given 12
hourly in two patients, and unfractionated heparin
maintaining the activated partial thromboplastin time
(aPTT) between 60 and 85 s was used in two patients.
TPN was initiated via a central line. Triple antibiotics
comprising of second-generation cephalosporins, ami-
noglycoside, and metronidazole were used. Our
divisional policy is that immediate exploratory lapar-
otomy is indicated where signs of peritonitis are
present. This diagnosis is based on radiological
findings such as a transmural gas shadow within the
bowel wall irrespective of the leucocyte count.
Laparotomy was not indicated in any patient in this
series. All of the SMVT and PVT recanalised regaining
at least 50% lysis of the thrombus on CT scanning
during follow-up period. All patients were advised to
continue life-long anticoagulation with warfarin.Complications
Cavernous transformation of the portal vein devel-
oped in four patients (Fig. 5). During the follow-up
period, two patients presented with symptoms of
small bowel obstruction after 1.5 and 4 months
following initial anticoagulant therapy. Contrast radi-
ology with an upper gastrointestinal swallow and
small bowel study showed a stricture of the small
bowel. The location of the stricture in one patient was
at the jejunum 50 cm distal to the Treitz ligament, 3 cm
in length, and 0.8 cm in external diameter. In the other
patient, the stricture was in the jejunum 70 cm distal to
the Treitz ligament, 3.5 cm in length. We resected the
strictures with anastomosis of the small bowel.
Histological examination showed segmental stenosisEur J Vasc Endovasc Surg Vol 29, February 2005
Fig. 1.CTscan shows the enlargement of superior mesenteric
vein with central area of low attenuation representing
intraluminal thrombus (white arrow).
Fig. 3. CT scan after 30 days: more recanalised superior
mesenteric vein (white arrow).
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bined with venous thrombosis. There was a pleural
effusion in two patients and oesophageal varices in
two patients.Clinical outcome
To date, there has been no mortality. The mean follow-
up period is 32 months (range: 1–79 months). The
mean duration of hospitalisation was 31 days (range:
13–63 days).Discussion
The clinical diagnosis of SMVT has evaded cliniciansFig. 2. CT scan after 10 days: partially recanalised superior
mesenteric vein (white arrow).
Eur J Vasc Endovasc Surg Vol 29, February 2005for decades; consequently, the true incidence of this
condition is unknown. In autopsy studies, SMVT is
found in approximately 1.5% of the population.7
Traditionally, MVT is grouped under the category of
mesenteric ischaemia. Ottinger and Austen found
venous thrombus in 0.06% of the patients with
mesenteric ischaemia at the Massachusetts General
Hospital.8 Risk factors for venous thrombosis include
hypercoagulable states, portal hypertension, trauma,
post-splenectomy, malignancy, inflammatory states,
pregnancy, and oral contraceptive use.9–12 In youngFig. 4. Small bowel series showing stricture of the small
bowel, severe dilatation of proximal portion and no passage
of barium to the distal portion (white arrow).
Fig. 5.Cavernous transformation of hepatic hilum (shown by
the ellipse).
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thrombosis, a thorough workup for primary hyper-
coagulable states is warranted. Overall, the most
common cause is myeloproliferative disease. Other
causes include genetic factors such as: factor V Leiden
gene mutation (activated protein C resistance); hyper-
homocysteinemia; hyperfibrinogenemia; paroxysmal
nocturnal haemoglobinuria; antithrombin III
deficiency; protein C deficiency; protein S deficiency;
or acquired risk factors such as antiphospholipid
antibody or anticardiolipin antibody syndromes,
collagen vascular disease, or dysfibrinogenemia.9–12
In our series, the most common condition predispos-
ing to combined SMVT and PVT was antithrombin III
deficiency.
In the past, an objective diagnosis of SMVT has been
difficult to establish. The use of the venous phase of a
selective mesenteric arteriogram may help13 but often
it is difficult to detect the actual filling defect. There-
fore, the diagnosis has depended on indirect findings
such as incomplete venous filling. Recently, contrast-
enhanced abdominal CT scan has been shown accu-
rately to detect portal vein, ovarian vein,14 and
mesenteric vein thrombosis.15 In our study, all the
SMVT and PVT were confirmed by abdominal CT
scanning. An immediate exploratory laparotomy was
indicated if peritonitis associated with bowel infarc-
tion was suspected. No patient in this series required
laparotomy. Regardless of whether surgical treatment
is needed, anticoagulation with heparin and treatment
with broad-spectrum antibiotics should begin
immediately because they decrease the risk of
rethrombosis and ultimately improve survival.4 In
patients with symptomatic MVT, endovascular treat-
ment has been reported with encouraging initialresults. The route of treatment was indirect intra-
arterial infusion of thrombolytic drugs through the
superior mesenteric artery.16–18 Indirect intra-arterial
infusion of thrombolytics is less technically demand-
ing and has the theoretic advantage of lysis of the
small venules of the mesentery. Some authors believe,
however, that indirect lysis is more unpredictable
because of preferential flow into collaterals. This
technique is generally associated with longer infusion
times.19
The portal vein may be accessed via transjugular or
transhepatic19,20 routes for pharmacological or mech-
anical thrombolysis have the advantage of a direct
approach to the system. The transhepatic route is
technically simpler than the transjugular approach.
The main disadvantage of the transhepatic route is the
risk of bleeding, especially in patients receiving
anticoagulation therapy and in patients with ascites.
Opitz et al. reported the use of a transjugular
intrahepatic portosystemic stent-shunt (TIPS).21 TIPS
initially served as a diagnostic tool allowing direct
angiography of the portal vein, the superior mesen-
teric vein and the splenic vein. The insertion of the
TIPS and subsequent thrombus fragmentation
achieved hepatic decompression and full recanalisa-
tion of the portal vein.
Surgical thrombectomy has been proposed,22,23
especially in patients at high risk of complications
from thrombolytic therapy. In patients with extensive
thrombosis of the portal vein and mesenteric vein,
thrombectomy could initially debulk the thrombus.
Pharmacological thrombolysis would probably still be
necessary to treat residual thrombosis after surgical
thrombectomy. Since, mesenteric and portal vein
thrombosis is a rare condition and the number of
cases reported is limited, it is hard to compare the
results of different approaches to treatment. Further
work is required to evaluate these possible therapies.References
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